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Regulatory T (Tregs) cells play an important role in mediating tolerance to self-antigens but can also mediate detrimental tolerance
to tumours and pathogens in a Foxp3-dependent manner. Genetic tools exploiting the foxp3 locus including bacterial artificial
chromosome- (BAC-) transgenic DEpletion of REGulatory T cells (DEREG) mice have provided essential information on Treg
biology and the potential therapeutic modulation of tolerance. In DEREG mice, Foxp3+ Tregs selectively express enhanced
green fluorescent protein (eGFP) and diphtheria toxin (DT) receptor, allowing for the specific depletion of Tregs through DT
administration.Wehere provide a detailed overview about an important consideration that long-term administration ofDT induces
a humoral immune response with an appropriate production of anti-DT antibodies that can inactivate DT and thus abrogate its
effect in theDEREGmouse. Additionally, we showed that anti-DTmouse serumpartially neutralizedDT-induced Foxp3 inhibition.
1. Introduction
Regulatory T (Tregs) cells play an important role inmediating
tolerance to self-antigens, and both their lineage and function
are specifically defined by the transcription factor Foxp3
[1, 2]. Foxp3 specifies the Treg cell lineage and is crucial
for immune tolerance against pathogens and tumour cells
[3–6]. Foxp3 reporter mice have been essential in order to
dissect the functions of Treg cells in vivo. One such mouse
strain, DEpletion of REGulatory T cells (DEREG), makes
use of a bacterial artificial chromosome (BAC) expressing
a diphtheria toxin receptor (DTR) and enhanced green
fluorescent protein (eGFP) fusion under control of the Foxp3
locus [7]. The vast majority of Foxp3+ Treg cells from
DEREG mice are depleted in response to DT [7]. It was
demonstrated that adult DEREGmice showed no observable
signs of illness after Treg cell depletion, while newborn
mice develop scurfy-like disease [7]. This has the unique
advantage that the in vivo function of Treg cells can be
studied in various settings in adult DEREG mice without the
mortality associated with uncontrolled autoimmunity. So far,
this model was mainly used to study a temporally transient
dysfunction of Tregs. Thus, Treg inactivation strategies in
view of studying a chronic and long-term DT administration
have not been addressed yet, according to our literature
search. Studies showed that following DT treatment of
na¨ıve DEREG mice, Treg depletion was transient with the
frequency of Foxp3+ Tregs returning to wild type (WT) levels
within 6 days. In addition, the newly emerged Foxp3+ Tregs
no longer expressed the DTR-eGFP transgene, thus prevent-
ing prolonged depletion. Similar results were observed in
mice undergoing either an acute or chronic viral infection.
Furthermore, DT treatment in both transgenic DEREGmice
and wild type (WT) mice resulted in enhanced morbidity
and mortality [8]. In preliminary (unpublished) experiments
using a murine infection model for alveolar echinococcosis
(larval infection with the fox tapeworm Echinococcus mul-
tilocularis), we were facing unexpected findings concerning
the time span of DT administration and the duration of
the expected effect of Treg inactivation. In this context, we
raised the question if long-term administration of DT could
(i) induce a humoral immune response with an appropriate
production of anti-DT antibodies that could inactivate DT
and thus (ii) abrogate its effect in the DEREG mouse.
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2. Material and Methods
2.1. Mice. Male DEREG mice, kindly provided by Professor
Manfred Kopf (ETH, Zurich, Switzerland) with the agree-
ment of Professor Tim Spawasser (TWINCORE, Hannover,
Germany), were backcrossed to wild type C57BL6 at the
animal facility of the Institute of Parasitology, University of
Bern (Bern, Switzerland). All the offsprings were genotyped
by PCR with specific primers for GFP and DTR. Foxp3+
Treg cell depletion was achieved by intraperitoneal (i.p.)
administration of 110 ng diphtheria toxin (DT) (A) 3 times per
week for 1, 2, 3, and 4 weeks. DT administration was stopped
after 4 weeks; Foxp3 and anti-DT antibody were determined
at indicated time-points. (B) TitratedDTwas injected i.p. at 0,
75, 150, and 300 ng; Foxp3 was determined by flow cytometry
at day 1 and day 3 after DT injection. (C) 110 ng DT was
injected i.p. 3 times per week at 1, 2, 3, and 4 weeks and then
stopped. Foxp3 was determined by flow cytometry at week 4
and week 16.
The animal study was performed in strict accordance
with the recommendations of the Swiss Guidelines for the
Care and Use of Laboratory Animals. The protocol was
approved by the Commission for Animal Experimentation of
the Canton of Bern (approval number BE 103/11).
2.2. Flow Cytometry. Aliquots of 105 spleen cells/100𝜇L of
staining buffer per well were incubated each with 1 𝜇g of
purified anti-CD16/CD32 for 20min in the dark in order to
block nonspecific binding of antibodies to the Fc𝛾III and
Fc𝛾II receptors. Subsequently these cells were stained with
surface marker separately for 15min with 1 𝜇g of PE-Cy5-
labelled anti-CD4 (GK1.5, eBioscience, San Diego, USA).
For intracellular staining, spleen cells were first incubated
with Inside Fix for 20mins at room temperature and then
stained with PE-labelled anti-Foxp3 (BD Pharmingen, Palo.
Alto, CA, USA) in Inside Perm for 15min in the dark.
Corresponding PE-labelled rat IgG2a (kappa chain) was used
as isotype control. Cells resuspended in 300𝜇L of buffer
(0.15MNaCl, 1mMNaH
2
PO
4
H
2
O, 10mMNa
2
HPO
4
2H
2
O,
and 3mM NaN
3
) were analysed in a flow cytometer (Becton
Dickinson, Heidelberg, Germany) using the corresponding
CELL QUEST software.
2.3. Enzyme-Linked Immunosorbent Assay (ELISA) for Anti-
DT Antibody Detection. ELISA plates (Nunc Immulon) were
coated with 100 𝜇L DT (Calbiochem, San Diego, CA, USA)
solution (5𝜇g DT/mL conventional carbonate/bicarbonate
coating buffer) overnight at +4∘C. After washing coated
plates 3 times with Tris-Tween buffered saline (TTBS), serum
samples (100 𝜇L, 1 : 50 dilution in TTBS plus 1mg/mL bovine
haemoglobin) were added to each well, and after 1-hour
incubation at 37∘C and three washes with TTBS, the wells
were incubated with alkaline phosphatase-conjugated anti-
mouse antibody (1 : 1000 dilution in TTBS, Lot number
0000103573, Promega, Madison, WI USA). Alkaline phos-
phatase substrate (1mg NPP/mL, Lot number 1001595631,
Sigma, Spruce St., USA) was then added, and absorbance
was measured at 405 nm using a Tecan Sunrise plate reader
(Tecan, Gro¨dig, Austria).
2.4. Anti-DT Serum Blocking. Six wild type C57BL6 mice
were injected 110 ng DT i.p. 3 times per week and kept
for another 4 weeks. Mice were sacrificed and blood was
taken by heart puncture. Serum levels of anti-DT antibody
were detected by ELISA, as described above. All serologically
positive sera were pooled. From this serum-pool, 200 𝜇L
was i.p. injected per mouse, and 110 ng DT was i.p. injected
per mouse one day later. All animals were sacrificed at the
3rd day after DT injection, and CD4+Foxp3+ frequency was
measured in spleen cell suspensions by using flow cytometry.
2.5. Statistical Analyses. All data were analyzed by SPSS
17.0. The results are presented as means ± SD. Normality of
data was assessed by D’Agostino and Pearson and Shapiro-
Wilk test. For normally distributed groups pf data, one-way
ANOVA or unpaired two-tail Student’s 𝑡-test was used to
compare the differences between groups. Significance was
defined as 𝑃 < 0.05 for all tests.
3. Results
3.1. Long-TermDTTreatment. In a first experiment, “titrated”
DT was intraperitoneally (i.p.) injected at 0, 75, 150, and
300 ng DT per mouse, and Foxp3 was measured at day
1 and day 3 after DT injection. Flow cytometric analyses
showed that Foxp3 was largely depleted by DT at 75 and
150 ng at day 1 (Foxp3 suppression rate of 87.3% and 88.3%,
resp., Figure 1(b)) but largely recovered at day 3 (Foxp3
suppression rate of 8.4% and 8.7%, resp., Figure 1(b)), while
there was only a partial recovery at 300 ng DT at day 3
(Foxp3 suppression rate of 61.3%, Figure 1(b)). Mice were
then treated with 110 ng DT/mouse and 3 times per week
and subsequently sacrificed at 4 and 16 weeks after treatment,
respectively. Flow cytometric analyses showed that Foxp3
was not depleted at week 4 and week 16 following DT
administration (Figure 1(c)).
3.2. Anti-DT Antibodies Were Produced 2 Weeks after DT
Treatment. To explore why Foxp3 was not depleted with
a continuous DT administration, that is, 4 weeks after
initiation of treatment, we examined serum levels of anti-
DT antibodies at different time-points. ELISA results showed
that, 2 weeks after DT treatment, serum levels of anti-DT
antibodies became detectable in all of the three mice, with,
however, a clear variation in the individual levels of anti-
DT antibodies concentrations (OD
405
2.016 versus 0.110).
Three weeks after DT administration, serum levels of anti-
DT antibodies were significantly higher in all of three mice
andmaintained a high level even another 4weeks after having
stopped DT administration, when compared to the levels
before DT administration (OD
405
3.44±0.24 at week 3 versus
0.17 ± 0.07 at week 0) (Figure 1(d)).
3.3. Anti-DT Serum Partially Neutralized DT-Induced Foxp3
Inhibition. To further study whether anti-DT antibodies
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Figure 1: Experimental design, Foxp3, and anti-DT antibody follow-up during chronic DT treatment. (a) Schematic presentation of the
experimental design. Foxp3+ Treg cell depletion was achieved by intraperitoneal (i.p.) administration of 110 ng diphtheria toxin (DT) 3 times
per week for 1, 2, 3, and 4 weeks. DT administration was stopped after 4 weeks; Foxp3 and anti-DT antibody were determined at indicated
time-points. (b) Titrated DT was injected i.p. at 0, 75, 150, and 300 ng; Foxp3 was determined by flow cytometry at day 1 and day 3 after DT
injection. (c) 110 ng DT was injected i.p. 3 times per week at 1, 2, 3, and 4 weeks and then stopped. Foxp3 was determined by flow cytometry
at week 4 and week 16. (d) Serum levels of anti-DT antibody were determined by using ELISA at indicated time-points. The mice were aged
8 weeks when used to start the initial DT treatment. ∗∗𝑃 < 0.01.
could neutralize DT-induced Foxp3 inhibition, we pro-
duced an anti-DT serum (pool of three DT-treated ani-
mals), and aliquots of this serum-pool were injected to
DEREG mice one day before DT application. Flow cytom-
etry results showed that anti-DT antibodies could partially
neutralize DT-induced Foxp3 inhibition, with Foxp3 per-
centage at 1.95 ± 0.11% (control), 0.26 ± 0.07% (with DT
administration), and 1.02 ± 0.09% (DT administration +
anti-DT serum injection), respectively (Figures 2(a) and
2(b)).
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Figure 2: Anti-DT serum blocking. (a) Representative images of Foxp3+ T cells within CD4+ T cells with/without anti-DT serum blocking.
(b) Frequency of Foxp3+ T cells within CD4+ T cells with/without anti-DT serum blocking. Six wild type C57BL6 mice were injected 110 ng
DT i.p. 3 times per week andmaintained for another 4 weeks. Mice were sacrificed and blood was taken from heart puncture. Serum anti-DT
antibody levels were detected by ELISA. Seropositive samples were pooled, and from this pool 200𝜇L anti-DT serum was injected i.p. per
mouse, and subsequently 110 ng DT/mouse was injected i.p. one day later. All the animals were sacrificed at the 3rd day, and CD4+Foxp3+
frequency in the spleen was measured by flow cytometry. ∗𝑃 < 0.05.
4. Discussion
In recent years, immunological studies within infectious
disease models have increasingly focused on the pathogen-
induced modulation of Treg function as a tool to improve
the survival potential of the infectious organisms [9, 10].
For a long time specific in vivo targeting of Tregs was
hampered by the lack of appropriate markers. The discovery
of Foxp3 as a Treg-specific transcriptional factor enabled the
development of Treg-specificmousemodels. In DEREGmice
(DEpletion of REGulatory T cells), a BAC (bacterial artificial
chromosome) transgenic mouse line allows direct in vivo
analysis and depletion of this exceedingly important cell type
[8]. DEREG mice carry a DTR-eGFP transgene under the
control of an additional Foxp3 promoter, thereby allowing
specific depletion of Tregs by application of diphtheria toxin
at any desired point of time during an on-going immune
response. Adult DEREG mice, depleted of Treg cells, lack
signs of autoimmune response [8]. Notably, this allowed for
the broad use of DEREG mice to document the involvement
of Treg cells in immune regulation and to gain insights
into Treg cell biology. The protection from autoimmunity
despite efficient transient Treg cell depletion is therefore
not a limitation but an advantage of DEREG mice [8].
Anticipated health side effects of DT applied to DEREG
mice as well as its efficiency to affect Treg function should
be controlled by careful dose titration of the DT treatment
in WT mice, previous to performing large-scale studies in
knock-out animals. Fromprevious studieswe could learn that
Treg cells were depleted by intraperitoneal injection of DT
either at a high dose (1 𝜇g DT/mouse), with an application
for three consecutive days [11], or medium dose (25𝜇g/kg
body weight, approximately 0.5 𝜇g DT/mouse) for one (days
0 and 1) or three rounds on two consecutive days (days
0, 1, 7, 8, 14, and 15) [12], or an initial dose of 200 ng DT
and 100 ng DT every third day for 15 days [13]. However, a
long-term DT administration that is persisting for 1 month
or up to 4 months with a low dose of DT has never been
studied, even though it may be very interesting to study
the role of Treg in vivo concerning chronic disease models
such as alveolar echinococcosis, where the parasite requires
many months to fully develop and reach fertility. In our
present study, we showed the possibility to treat DEREG
mice with a low dose (110 ng DT/mouse, 3 times/week)
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for 1 to 4 months without affecting the health status of
mice. However, while first conventionally depleted, Foxp3
became undepleted within 1 month of DT administration,
accompanied in parallel with a high level of anti-DT antibody
production by the treated animals. Subsequently we could
evidence that anti-DT antibodies partially abrogate DT-
induced Foxp3-inhibition by neutralizing DT in the mice,
with the result that Foxp3 became only partially depleted
after long-term DT administration. Teh and Gray discussed
an interesting point that could explain the mechanism that
ensures that the Treg niche is rapidly refilled following
depletion [14]. These Treg cells could be (i) the product
of peripheral conversion of activated conventional cells to
peripherally induced Treg (pTreg) cells or (ii) the product
of a homeostatic proliferation of existing thymus-derived
Treg (tTreg) cells. Evidence for the former is supported by
the authors’ observation that there was a 20% reduction
in Treg cells expressing neuropilin-1 (a cell surface marker
used to distinguish tTreg (neuropilin-1 high) from pTreg
(neuropilin-1 low) cells [15]), in the replenished Treg niche, as
compared to the original Treg cell population [14]. However,
it is noteworthy that neuropilin-1 may not be a reliable
marker for pTreg cells under inflammatory conditions [15],
which, however, seems to have been the case in their DT-
treated mice [14]. On the other hand, a separate study
found that homeostatic expansion of Treg cells (through
proliferation and reduced apoptosis) could completely restore
the compartment following 50% Treg cell depletion, with
no evidence of conversion of conventional T cells observed
[16]. This mechanism could be further confirmed due to
neutralizing effects regarding DT administration and Foxp3
inhibition.
5. Conclusions
In conclusion, our findings indicate that Foxp3 cannot be
kept knocked-down for a longer period of DT administration
due to subsequent anti-DT antibody synthesis by treated
animals and DT-neutralization via DT-specific antibodies.
These observations suggest that Foxp3 levels and anti-DT
antibody levels have to be carefully monitored in every
situation where DT treatment is used for more than 2 weeks.
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